Scarica l'app Stockscreener
1.85
9.47%
0.16
Dopo l'orario di chiusura:
1.87
0.02
+1.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$1.69
Aprire:
$1.7473
Volume 24 ore:
69,682
Relative Volume:
0.01
Capitalizzazione di mercato:
$9.51M
Reddito:
$1.38M
Utile/perdita netta:
$-179.05M
Rapporto P/E:
-0.3013
EPS:
-6.14
Flusso di cassa netto:
$-155.03M
1 W Prestazione:
+6.32%
1M Prestazione:
-19.21%
6M Prestazione:
+208.33%
1 anno Prestazione:
-31.73%
Intervallo 1D:
$1.73
$1.8775
Intervallo di 1 settimana:
$1.60
$1.8775
Portata 52W:
$0.16
$6.83
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Industria
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Confronta BTAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.85 | 9.51M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $1.72 - Investing.com
BioXcel Therapeutics Initiates At-The-Market Equity Program - Investing.com Australia
BioXcel Therapeutics Initiates At-The-Market Equity Program By Investing.com - Investing.com Canada
Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through CanaccordSEC Filing - MarketScreener
ROSEN, A RANKED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI - AsiaOne
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks
BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz
BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire
Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com India
BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World
BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com
BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India
Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Nasdaq
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting - MarketScreener
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
BioXcel's $35M Funding Boost Powers Breakthrough At-Home Mental Health Treatment Trial - StockTitan
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - MSN
BioXcel Therapeutics reaches 33% enrollment in trial By Investing.com - Investing.com Australia
BioXcel Therapeutics reaches 33% enrollment in trial - Investing.com
BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025 - Nasdaq
BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial - TipRanks
BioXcel Therapeutics Announces 33% Enrollment in SERENITY - GlobeNewswire
Could This Be the First FDA-Approved At-Home Treatment for Bipolar and Schizophrenia Agitation? - StockTitan
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.04%
2.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):